Follistatin-Like 1 Attenuates Apoptosis via Disco-Interacting Protein 2 Homolog A/Akt Pathway After Middle Cerebral Artery Occlusion in Rats

Xiping Liang, MD*; Qin Hu, MD, PhD*; Bo Li, MD, PhD; Devin McBride, PhD; Hetao Bian, MD; Pierre Spagnoli, BS; Di Chen, MD, PhD; Jiping Tang, MD; John H. Zhang, MD, PhD

Background and Purpose—Follistatin-like 1 (FSTL1), an extracellular glycoprotein, has been reported to decrease apoptosis in ischemic cardiac diseases, but its effect in ischemic stroke has not been examined. We hypothesized that recombinant FSTL1 attenuates neuronal apoptosis through its receptor disco-interacting protein 2 homolog A (DIP2A) and the Akt pathway after middle cerebral artery occlusion (MCAO) in rats.

Methods—One hundred forty male Sprague-Dawley rats were subjected to 2 hours of MCAO followed by reperfusion. In a subset of animals, the time course and location of FSTL1 and DIP2A were detected by Western blot and immunofluorescence double staining. Another set of animals were intracerebroventricularly given either recombinant FSTL1 1 hour after reperfusion or FSTL1-small interfering RNA (siRNA) 48 hours before reperfusion. Additionally, DIP2A was knockdown by siRNA in some animals. Infarction volume and neurological deficits were measured, and the expression of FSTL1, DIP2A, phosphorylated Akt, cleaved caspase-3, and terminal deoxynucleotidyl transferase dUTP nick end labeling were quantified using Western blot.

Results—The expression of FSTL1 and DIP2A was increased in neurons and peaked 24 hours after MCAO. Recombinant FSTL1 reduced brain infarction and improved neurological deficits 24 and 72 hours after MCAO via activation of its receptor DIP2A and downstream phosphorylation of Akt. These effects were reversed by DIP2A-siRNA and FSTL1-siRNA.

Conclusions—Recombinant FSTL1 decreases neuronal apoptosis and improves neurological deficits through phosphorylation of Akt by activation of its receptor DIP2A after MCAO in rats. Thus, FSTL1 may have potentials as a treatment for patients with ischemic stroke. (Stroke. 2014;45:3048-3054.)

Key Words: apoptosis • follistatin-related proteins • infarction, middle cerebral artery

Stroke is one of the leading causes of morbidity and mortality worldwide, of which >80% are ischemic caused by obstruction of the cerebral arteries.1 Currently, tissue-type plasminogen activator is the only Food and Drug Administration–approved treatment for acute ischemic stroke and is given to =2% to 5% of patients with stroke.2 However, tissue-type plasminogen activator has a few limitations which fuel the interest in the development of new neuroprotective therapies. Recent studies have revealed that stroke-induced neuron apoptosis, predominantly in the ischemic penumbra or peri-infarct zone, may be caspase dependent. Thus, neuronal apoptosis is potentially recoverable in the early stage after stroke onset,3 and a treatment manipulating apoptotic pathways remains an appealing strategy.

Follistatin-like 1 (FSTL1) is an extracellular glycoprotein that belongs to the follistatin family of proteins. Accumulating evidence indicates that FSTL1 has protective effects on ischemia–reperfusion injury in muscle and heart tissue associated with antiapoptosis.4,5 The plasma protein levels of FSTL1 were increased after ischemia injury or under hypoxia/reoxygenation stress in the heart or hind limb.6,7 Elevated levels of circulating FSTL1 were also observed in patients with heart failure.8 These findings suggest that FSTL1 may have broad cardiovascular-protective activities in heart ischemia. The protective effects of FSTL1 against apoptosis in cardiac ischemia were mediated by activation of the receptor disco-interacting protein 2 homolog A (DIP2A) and phosphorylation of Akt.8 However, the therapeutic impact of FSTL1 and its receptor...
DIP2A on brain ischemia has not been previously investigated nor the molecular mechanisms underlying the effects of FSTL1 on neuron apoptosis. The present study aims to investigate the neuroprotective effect and potential molecular mechanisms of FSTL1 in a rat middle cerebral artery occlusion (MCAO) model.

Materials and Methods

Animal Model and Experimental Protocol
All experiments were approved by the Institutional Animal Care and Use Committee of Loma Linda University. Sprague-Dawley male rats weighting 260 to 300 g were subjected to MCAO as previously described,9 with some modifications. Briefly, anesthesia was induced intraperitoneally with ketamine (80 mg/kg) and xylazine (10 mg/kg) followed by atropine at a dose of 0.1 mg/kg. The right common carotid artery, internal carotid artery, and external carotid artery were surgically exposed. The external carotid artery was coagulated, and 4-0 nylon suture with silicon was inserted into the internal carotid artery through the external carotid artery stump to occlude the MCA. After 2 hours of MCAO, the suture was carefully removed to induce reperfusion. Sham rats underwent the same procedures except that the MCA was not occluded. After closing the skin incision, rats were kept at 37°C on an electric heating blanket and were housed separately until completely recovered from anesthetic.

To test whether delivery of FSTL1 protein affects acute brain ischemic injury in rats, male Sprague-Dawley rats were injected intracerebroventricularly with either 1 of 2 dosages of recombinant FSTL1 protein (R&D Systems, 100 or 300 mg/kg) or vehicle (0.1 mol/L PBS) at 1 hour after reperfusion.

siRNA Injection
Three different formats of FSTL1-small interfering RNA (siRNA) (OriGene Technologies) or DIP2A-siRNA (Santa Cruz Biotechnology) were applied 48 hours before MCAO by intracerebroventricular injection (ICV) as previously described.10 A scalp incision was made along the midline, and a burr hole (1 mm) was drilled into the skull above the right hemisphere (1.0 mm lateral of the bregma). The FSTL1-siRNA or DIP2A-siRNA mixture or scramble-siRNA (100 pmol/2 μL) was delivered into the ipsilateral ventricle with a Hamilton syringe and administered for 2 minutes. The needle was left in place for an additional 5 minutes after injection to prevent possible leakage and was then slowly withdrawn after 4 minutes. After the needle was removed, the burr hole was sealed with bone wax. The incision was closed with sutures, and the rat was allowed to recover.

Neurological Scores
Twenty-four or 72 hours after MCAO, the Garcia test was performed by a blinded investigator as previously described with modifications.11 The score given to each rat at completion of the evaluation was the summation of 7 individual test scores (spontaneous activity, symmetry in the movement of 4 limbs, forepaw outstretching, climbing, body proprioception, response to vibrissae touch, and beam walking). The neurological scoring ranged from 2 (most severe deficit) to 21 (maximum).

2,3,5-Triphenyltetrazolium Chloride Staining
Infarction volume was determined by staining with 2,3,5-triphenyltetrazolium chloride (Sigma) at 24 and 72 hours after MCAO as previously described with some modification.11 Briefly, general anesthesia was reintroduced with a mixture of ketamine and xylazine and decapitated; the brains were rapidly removed and sectioned coronally into 2-mm thick slices starting from the frontal pole. Slices were stained with 2,3,5-triphenyltetrazolium chloride for 15 minutes at 37°C. The infarct and total hemispheric areas of each section were traced and analyzed using ImageJ (ImageJ, National Institutes of Health). The possible interference of brain edema with infarct volume was corrected by standard methods (whole contralateral hemisphere volume−nonischemic ipsilateral hemisphere volume), and the infarcted volume was expressed as a ratio of the corrected infarct to the whole contralateral hemisphere.

Immunofluorescence Staining
Rats were euthanized 24 hours after MCAO for double immunofluorescence staining as previously described,12 using the neuronal marker of neuronal nuclei (NeuN; Millipore), FSTL1 (sc-12542, Santa Cruz Biotechnology), and DIP2A (sc-67556, Santa Cruz Biotechnology). Brain sections were incubated with a mixture of either NeuN and FSTL1 or NeuN and DIP2A primary antibodies overnight at 4°C, followed by a mixture of secondary antibodies for 1 hour at room temperature. Microphotographs were analyzed with a fluorescent microscope (Olympus OX51, Japan).

Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling Staining
Twenty-four hours after MCAO, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed with In Situ Apoptosis Detection Kit (Roche) according to the manufacturer’s instruction. Four images were taken from the ischemic border of each section using a ×40 objective lens and then the number of TUNEL-positive neurons and the number of TUNEL-positive non-neurons were counted. The total number of neurons and non-neurons in the ischemic hemisphere at ×40 magnification were counted in 3 arbitrary fields. The number of TUNEL-positive neurons or non-neurons was expressed as a ratio to that in MCAO+vehicle group, respectively.

Western Blots
Brain samples were collected 24 hours after MCAO. Proteins of the ipsilateral hemisphere were extracted by homogenizing in radio-immunoprecipitation assay lysis buffer (sc-24948, Santa Cruz Biotechnology). Western blotting was performed as described previously.12 Primary antibodies used were FSTL1 (sc-12542, Santa Cruz Biotechnology), DIP2A (sc-67556, Santa Cruz Biotechnology), phosphorylated Akt (Cell Signaling Technology), cleaved caspase-3 (Cell Signaling Technology), and goat polyclonal β-actin (sc-1616, Santa Cruz Biotechnology).

Statistical Analysis
Data from different groups were compared using 1-way ANOVA followed by post hoc Tukey tests. The data are presented as mean±SEM. A value of P<0.05 was considered statistically significant.

Results

Expressions of FSTL1 and DIP2A Were Increased in Neurons and Peaked 24 Hours After MCAO
The protein level of FSTL1 and DIP2A at 6, 12, 24, and 48 hours in the ischemic penumbra after MCAO were measured by Western blot. Analysis showed that FSTL1 began increasing as early as 6 hours after ischemia, peaking at 12 hours, and was sustained to 24 hours (both 12 and 24 hours were statistically significant from sham, P<0.05). FSTL1 returned to a level indistinguishable from sham by 48 hours (Figure 1A and 1B). A similar trend was observed for the expression of DIP2A, the FSTL1 receptor; DIP2A significantly increased at 12 and 24 hours after MCAO and returned back to sham levels at 48 hours (Figure 1C). Double immunofluorescence staining of FSTL1 and NeuN or DIP2A and NeuN showed that both FSTL1 and DIP2A were upregulated in neurons in the penumbra 24 hours after MCAO. FSTL1 was primarily
expressed in the cytoplasm, and DIP2A is located in the membranes of neurons (Figure 1D).

**Recombinant FSTL1 Reduced Brain Infarction and Improved Neurological Function 24 and 72 Hours After MCAO**

Analysis of the infarct stained with 2,3,5-triphenyltetrazolium chloride showed that the ratio of the infarcted tissue volume to the volume of the contralateral tissue 24 hours after MCAO was 0.334±0.1102. Administering the vehicle did not significantly reduce the infarct ratio (0.324±0.1302; \( P > 0.05 \) versus MCAO). Treatment with the low dose of FSTL1 (100 mg/kg) had an infarct ratio of 0.2194±0.0395 (\( P > 0.05 \) versus MCAO). However, treatment with the high dose of FSTL1 (300 mg/kg) significantly decreased the infarct ratio (Figure 2A and 2B; 0.190±0.0397; \( P < 0.05 \) versus MCAO).

MCAO resulted in neurological deficits 24 hours after MCAO (\( P < 0.05 \) versus sham). Administering the vehicle or low dose of FSTL1 did not have any significant effect on neurological deficits. Yet, the high dose of FSTL1 significantly improved the neurological function of rats 24 hours after MCAO (Figure 2C; \( P < 0.05 \) versus MCAO).

Seventy-two hours after MCAO, the infarct ratio was 0.3193±0.0775 in untreated group (MCAO) and 0.3222±0.0536 in the vehicle-treated group (MCAO+vehicle). FSTL1 at a dose of 300 mg/kg significantly decreased the infarct ratio compared with MCAO (0.151±0.0382; \( P < 0.05 \) versus MCAO). Furthermore, FSTL1 significantly improved the performance of MCAO rats on the neurobehavioral tests (Figure 3C; \( P < 0.05 \) versus MCAO).

FSTL1 Decreased Neuronal Apoptosis Through Phosphorylation of Akt

Twenty-four hours after MCAO, there were abundant TUNEL-positive neurons in the ischemic penumbra, and treatment with 300 mg/kg FSTL1 decreased the number of TUNEL-positive neurons (Figure 4A and 4B; \( P < 0.05 \) versus MCAO+vehicle). Knockdown of FSTL1 by intracerebroventricular injection of FSTL1-siRNA 48 hours before MCAO significantly increased the number of TUNEL-positive neurons when compared with either the MCAO+vehicle or the scramble-siRNA group (Figure 4A and 4B; \( P < 0.05 \) versus MCAO+vehicle and MCAO+scramble-siRNA). Neurological function was exacerbated by FSTL1-siRNA (Figure 4B; \( P < 0.05 \) versus MCAO+vehicle and MCAO+scramble-siRNA). Additionally, administration of FSTL1 reduced the number of TUNEL-positive non-neuronal cells, FSTL1-siRNA increased the number of TUNEL-positive non-neuronal cells, and FSTL1+DIP2A-siRNA increased the number of TUNEL-positive non-neuronal cells (Figure I in the online-only Data Supplement).

Western blot analysis showed that administration of FSTL1 significantly increased the expression of FSTL1 and enhanced the phosphorylation of Akt (Figure 4C and 4D; \( P < 0.05 \) versus MCAO+vehicle). FSTL1-siRNA effectively suppressed the expression of FSTL1 and reduced the level of phosphorylated Akt 24 hours after MCAO (Figure 4C and 4D; \( P < 0.05 \) versus MCAO+vehicle, MCAO+FSTL1, and MCAO+scramble-siRNA).

**FSTL1 Phosphorylation of Akt Is Dependent on Its Receptor DIP2A**

DIP2A-siRNA was injected intracerebroventricularly 48 hours before MCAO, and rats were treated with FSTL1 1 hour after MCAO. DIP2A-siRNA abolished the effects of FSTL1 by increasing neuron apoptosis (Figure 5A and 5B, increased TUNEL-positive neurons, \( P < 0.05 \) versus MCAO+FSTL1+scramble-siRNA group) and increasing the neurological deficits (Figure 5C; \( P < 0.05 \) versus MCAO+FSTL1+scramble-siRNA group). Western blot analysis showed that administration of FSTL1 significantly increased the expression of FSTL1 and enhanced the phosphorylation of Akt (Figure 4C and 4D; \( P < 0.05 \) versus MCAO+vehicle). FSTL1-siRNA effectively suppressed the expression of FSTL1 and reduced the level of phosphorylated Akt 24 hours after MCAO (Figure 4C and 4D; \( P < 0.05 \) versus MCAO+vehicle, MCAO+FSTL1, and MCAO+scramble-siRNA).
analysis showed that DIP2A-siRNA reduced the expression of DIP2A, decreased the level of phosphorylation of Akt, and raised the level of cleaved caspase-3 (Figure 6; P<0.05 versus MCAO+FSTL1+scramble-siRNA group).

**Discussion**

Apoptosis has been suggested to play a role in neuronal death after stroke in patients as well as in animal models of stroke. Cerebral ischemia triggers 2 general pathways of apoptosis: the intrinsic pathway that originates from mitochondrial release of cytochrome c and associated stimulation of caspase-3 and the extrinsic pathway that originates from the activation of cell surface death receptors and subsequent stimulation of caspase-8. Neurons in the ischemic penumbra or peri-infarct zone undergo apoptosis within hours after stroke onset. Targeting and preventing apoptosis in the penumbra would seem to be a logical therapeutic goal for limiting cerebral infarct volume after stroke. In the present study, we showed that administration of recombinant FSTL1 can reduce infarction volume and improve neurological function.
by suppressing neuron apoptosis after MCAO in rats. We also found that the ant apoptotic mechanism of FSTL1 treatment is via decreased caspase-3 cleavage through phosphorylation of Akt by activation of the FSTL1 receptor, DIP2A. These observations suggested that treatment with FSTL1 might be a potential therapeutic intervention for reducing infarction in patients with ischemic stroke.

FSTL1 was originally identified from a transforming growth factor–responsive gene in osteoblast cells that have a follistatin-like domain. Although developmental studies have suggested that FSTL1 regulates organ tissue formation in embryos, its functions in fully developed tissue have only been partially elucidated. FSTL1 has been reported to suppress cancer and modulate inflammation in animals. Recently, accumulating evidence indicates FSTL1 is cardiac protective after ischemia stress. Upregulation of FSTL1 transcription was observed in the hearts of Akt1 transgene-induced hypertrophy mice, and FSTL1 levels are increased in patients with acute coronary syndrome or heart failure.

In experimental cardiac ischemia, systemic administration of FSTL1 was protective and suggested to be antiapoptotic. Additionally, administration of FSTL1 accelerated revascularization in the hind-limb ischemia model, and in vitro studies demonstrated an antiapoptotic effect of FSTL1 on primary endothelial cells. The results of these studies suggest that FSTL1 functions as an antiapoptotic protein after ischemia. However, little is known about its function in cerebrovascular disease. We found that FSTL1 was endogenously expressed in brain and was robustly increased 12 hours after MCAO. FSTL1 was observed in the cytoplasm of neurons. This study also provides additional evidence of the antiapoptotic function of FSTL1 after ischemia. Administration of recombinant FSTL1 decreased infarction volume and improved neurological function by reducing apoptosis, and knockdown of FSTL1

Figure 4. Follistatin-like 1 (FSTL1) decreased apoptosis by increasing Akt phosphorylation 24 hours after middle cerebral artery occlusion (MCAO). A, Immunofluorescence double staining of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)–positive cells (green) and neurons (neuronal nuclei [NeuN], red). B, TUNEL-positive neurons are decreased by FSTL1 and increased by FSTL1-siRNA. Neurological score is improved by FSTL1 and reduced by FSTL1-siRNA. C, Western blot analysis of FSTL1 expression. D, Western blot analysis of phosphorylated Akt (p-Akt). Akt phosphorylation is increased by FSTL1 and reversed by FSTL1-siRNA. Discoid-interacting protein 2 homolog A (DIP2A; 96 kDa), FSTL1 (35 kDa), and β-actin (42 kDa) were run on the same gel. n=6 for each group in Western blot and immunohistochemistry. & $P<0.05$ vs MCAO+vehicle, # $P<0.05$ vs MCAO+scramble-siRNA. Bars, 100 μm.
exacerbates these outcomes. Furthermore, FSTL1 was found to decrease apoptosis both in neurons and non-neuronal cells, suggesting that FSTL1 may play a role in other cell types after cerebral ischemia.

The serine/threonine protein kinase Akt (also known protein kinase B) is a key regulator of cell growth and survival and is essential for cellular adaptation to stress. Therefore, Akt plays a role in several critical pathways making it a compelling target for neuroprotection after brain ischemia. FSTL1 has been implicated in the protection of cardiovascular cells from stress via the activation of phosphatidylinositol 3-kinase and Akt signaling.6 In endothelial cells, FSTL1 activation of phosphatidylinositol 3-kinase/Akt signaling led to the activation of endothelial nitric oxide synthase and subsequent nitric oxide production.5 In this study, it was found that recombinant FSTL1 increases the phosphorylation of Akt 24 hours after MCAO, and knockdown of FSTL1 has the reverse effect.

Although FSTL1 is categorized as a follistatin-like protein, there is relatively little functional similarity with other follistatin family proteins which are binding partners of the transforming growth factor beta. Figure 6. Follistatin-like 1 (FSTL1) prevented apoptosis though the disco-interacting protein 2 homolog A (DIP2A)/Akt pathway after middle cerebral artery occlusion (MCAO) in rats. Western blots for DIP2A, Akt, and cleaved caspase-3 (CC3; A) showed that DIP2A-siRNA prevented the expression of DIP2A after FSTL1 treatment (B), reduced Akt phosphorylation (C), and increased the expression of CC3 (D). n=6 for each group. &P<0.05 vs MCAO+vehicle; @P<0.05 vs MCAO+FSTL1+scramble-siRNA.
growth factor-β family proteins. Recently, DIP2A was found to function as an FSTL1 receptor. In endothelial cells, DIP2A functions in the antiapoptotic effects of FSTL1 and mediates FSTL1 activation of Akt.1 DIP2A has been observed on the surface of endothelial cells, and knockdown of DIP2A by siRNA reduced the binding of FSTL1. Furthermore, in endothelial cell cultures, DIP2A knockdown diminishes FSTL1-stimulated survival, migration, and differentiation in network structures and inhibited FSTL1-induced Akt phosphorylation. Finally, DIP2A was also identified as a candidate receptor molecule for FSTL1 by molecular interaction methods.20 To determine the mechanism of FSTL1 in Akt phosphorylation after focal cerebral ischemia, we first examined the localization of DIP2A and FSTL1. We found that both DIP2A and FSTL1 were primarily expressed by neurons and increased 24 hours after MCAO, indicating that locally produced FSTL1 may activate signaling pathways through the DIP2A receptor. Knockdown of DIP2A by siRNA removed the antiapoptosis effects of FSTL1 via decreased the Akt phosphorylation after MCAO in rats.

In conclusion, our findings indicate that FSTL1 may contribute to neuronal survival after brain ischemia. FSTL1 inhibited apoptosis through phosphorylation of Akt via activation of its receptor, DIP2A. This study provides new information on the function of FSTL1 following MCAO and makes FSTL1 a potential therapeutic candidate for patients with ischemic stroke.

Sources of Funding
This study was supported partially by a grant from National Institutes of Health NS043338 (Dr Zhang).

Disclosures
None.

References
Follistatin-Like 1 Attenuates Apoptosis via Disco-Interacting Protein 2 Homolog A/Akt Pathway After Middle Cerebral Artery Occlusion in Rats
Xiping Liang, Qin Hu, Bo Li, Devin McBride, Hetao Bian, Pierre Spagnoli, Di Chen, Jiping Tang and John H. Zhang

Stroke. 2014;45:3048-3054; originally published online August 19, 2014;
doi: 10.1161/STROKEAHA.114.006092
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/45/10/3048

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2014/08/19/STROKEAHA.114.006092.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL

FSTL1 Attenuates Apoptosis via DIP2A/Akt Pathway after MCAO in Rats

Xiping Liang M.D., Qin Hu M.D., Ph.D., Bo Li M.D., Ph.D., Devin McBride Ph.D., Hetao Bian M.D., Pierre Spagnoli B.S., Di Chen M.D., Ph.D., Jiping Tang M.D., John H Zhang M.D., Ph.D.

1Departments of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA, USA; 2Departments of Neurosurgery, Loma Linda University School of Medicine, Loma Linda, CA, USA; 3Departments of neurology, Chongqing Medical University, Chongqing, China.

# These authors contributed equally to this work.
*Corresponding author: John H. Zhang, M.D., Ph.D., Department of Neurosurgery and Department of Physiology and Pharmacology, Loma Linda University School of Medicine, 11041 Campus street, Risley Hall, Room 219, Loma Linda, CA, 92354, USA. E-mail: johnzhang3910@yahoo.com, Phone: 909-558-4723, Fax: 909-558-0119.
Supplemental Figures and Figure Legends

Supplement figure I. Statistical analysis of TUNEL positive non-neuronal cells in Figure 4A (A) and Figure 5A (B). n=6 for each group, &p<0.05 vs. MCAO+Vehicle, #p<0.05 vs. MCAO+Scramble-siRNA, @p<0.05 vs. MCAO+FSTL1+Scramble-siRNA.